2024-07-15CytoArm Licenses CD19 Armed-T cell for Blood Cancer Drug Development to SL-LINK CompanyContinue ReadingCytoArm Licenses CD19 Armed-T cell for Blood Cancer Drug Development to SL-LINK Company
2024-05-20Join us at BIO 2024, June 3-6 in San DiegoContinue ReadingJoin us at BIO 2024, June 3-6 in San Diego
2024-05-20CytoArm’s CEO Wins Top Honor as Taiwan’s Young Biomedical LeaderInnovative Armed-T Technology for Cancer TreatmentContinue ReadingCytoArm’s CEO Wins Top Honor as Taiwan’s Young Biomedical LeaderInnovative Armed-T Technology for Cancer Treatment
2024-05-20CytoArm’s CEO Interviewed by Commonwealth Publishing Magazine: New Hope for Cancer TreatmentContinue ReadingCytoArm’s CEO Interviewed by Commonwealth Publishing Magazine: New Hope for Cancer Treatment